Stay updated on ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page.

Latest updates to the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4. This indicates a minor version update to the page rendering/content management, with no substantive changes to study data or user-facing information.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page’s revision/version indicator has been updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a software release rather than a change to the clinical trial information.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check80 days agoChange DetectedNo additions or deletions were detected between the old and new screenshots; the page content appears unchanged.SummaryDifference0.1%

Stay in the know with updates to ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page.